A20 in Kidney Transplantation and Autoimmunity

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 27

PMID 38928333

Authors

Andreas Kommer

Myriam Meineck

Paul Classen

Julia Weinmann-Menke

Affiliations

Soon will be listed here.

Abstract

A20, the central inhibitor of NFκB, has multiple anti-inflammatory properties, making it an interesting target in kidney autoimmune disease and transplant biology. It has been shown to be able to inhibit inflammatory functions in macrophages, dendritic cells, T cells, and B cells in various ways, leading to less tissue damage and better graft outcomes. In this review, we will discuss the current literature regarding A20 in kidney transplantation and autoimmunity. Future investigations on animal models and in existing immunosuppressive therapies are needed to establish A20 as a therapeutic target in kidney transplantation and autoimmunity. Cell-based therapies, modified viruses or RNA-based therapies could provide a way for A20 to be utilized as a promising mediator of inflammation and tissue damage.

References

Ahn K, Aggarwal B . Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci. 2006; 1056:218-33. DOI: 10.1196/annals.1352.026. View

Karri U, Harasimowicz M, Tumba M, Schwartz D . The Complexity of Being A20: From Biological Functions to Genetic Associations. J Clin Immunol. 2024; 44(3):76. DOI: 10.1007/s10875-024-01681-1. View

Avihingsanon Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Giraldo M . Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. Transplantation. 2002; 73(7):1079-85. DOI: 10.1097/00007890-200204150-00011. View

Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D . Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11(10):2093-109. DOI: 10.1111/j.1600-6143.2011.03686.x. View

Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley S, Beyaert R . Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol. 2010; 80(12):2009-20. DOI: 10.1016/j.bcp.2010.06.044. View

Chandel N, Trzyna W, McClintock D, Schumacker P . Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol. 2000; 165(2):1013-21. DOI: 10.4049/jimmunol.165.2.1013. View

Dong B, Lv G, Wang Q, Wei F, Bellail A, Hao C . Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2012; 418(2):433-8. DOI: 10.1016/j.bbrc.2012.01.056. View

Avihingsanon Y, Ma N, Pavlakis M, Chon W, Uknis M, Monaco A . On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol. 2005; 16(6):1542-8. PMC: 1350948. DOI: 10.1681/ASN.2005020210. View

Siracuse J, Fisher M, da Silva C, Peterson C, Csizmadia E, Moll H . A20-mediated modulation of inflammatory and immune responses in aortic allografts and development of transplant arteriosclerosis. Transplantation. 2012; 93(4):373-82. PMC: 3275666. DOI: 10.1097/TP.0b013e3182419829. View

10.

Ahrens H, Petersen B, Ramackers W, Petkov S, Herrmann D, Hauschild-Quintern J . Kidneys From α1,3-Galactosyltransferase Knockout/Human Heme Oxygenase-1/Human A20 Transgenic Pigs Are Protected From Rejection During Ex Vivo Perfusion With Human Blood. Transplant Direct. 2016; 1(6):e23. PMC: 4946468. DOI: 10.1097/TXD.0000000000000533. View

11.

Han J, Wang Y, Li H, Alateng C, Bai Y, Sun Z . Single nucleotide polymorphisms of TNFAIP3 are associated with systemic lupus erythematosus in Han Chinese population. Int J Immunogenet. 2016; 43(2):96-100. DOI: 10.1111/iji.12250. View

12.

Daniel S, Patel V, Shrikhande G, Scali S, Ramsey H, Csizmadia E . The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells. Transplant Proc. 2006; 38(10):3225-7. PMC: 2866740. DOI: 10.1016/j.transproceed.2006.10.167. View

13.

Bai W, Huo S, Li J, Shao J . Advances in the Study of the Ubiquitin-Editing Enzyme A20. Front Pharmacol. 2022; 13:845262. PMC: 9110840. DOI: 10.3389/fphar.2022.845262. View

14.

Odqvist L, Jevnikar Z, Riise R, Oberg L, Rhedin M, Leonard D . Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(10):1363-1370. PMC: 6788882. DOI: 10.1136/annrheumdis-2019-215434. View

15.

Shi Y, Wang X, Wang J, Wang X, Zhou H, Zhang L . The dual roles of A20 in cancer. Cancer Lett. 2021; 511:26-35. DOI: 10.1016/j.canlet.2021.04.017. View

16.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

17.

Parvatiyar K, Harhaj E . Regulation of inflammatory and antiviral signaling by A20. Microbes Infect. 2010; 13(3):209-15. PMC: 3031767. DOI: 10.1016/j.micinf.2010.11.003. View

18.

Pu T, Liu W, Wu Y, Zhao Y . A20 functions as a negative regulator in macrophage for DSS-induced colitis. Int Immunopharmacol. 2021; 97:107804. DOI: 10.1016/j.intimp.2021.107804. View

19.

Sun L, Zou L, Han Y, Zhu D, Chen T, Wang J . Role of A20/TNFAIP3 deficiency in lupus nephritis in MRL/lpr mice. Clin Exp Nephrol. 2019; 24(2):107-118. DOI: 10.1007/s10157-019-01826-2. View

20.

Smith S, Hosgood S, Nicholson M . Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells. Kidney Int. 2019; 95(1):50-56. DOI: 10.1016/j.kint.2018.10.009. View